Using cutting-edge technology and innovative therapies, WideCells Group is aiming to increase the number of diseases treatable with stem cells and make treatment accessible and affordable globally. Much of its focus is on growing the company’s knowledge of blood diseases and using leading technology to provide cell-banking services for a wide range of human tissues. However, it is also aiming to become the world’s market-leading provider of stem cell services; protecting as many families and individuals as possible from the financial consequences of blood cancers by providing insurance for stem-cell treatment and accessibility to the best care worldwide.
How they’re disrupting
WideCells Group is providing the world’s first global health-care plan, bringing accessibility and affordability to the treatment of blood diseases and disorders and making stem-cell treatment a reality for families. They’re also working with universities and other researchers to create stem cell training courses for healthcare professionals, to develop more experts in the field and conducting stem cell processing & storage for a wide range of human tissues at their laboratory facilities – Institute of Stem Cell technology – located at the University of Manchester Innovation Centre, and also supporting stem cell research via contract & development projects.
It’s estimated that the stem cell industry in worth $100 billion today and will be worth $170 billion by 2020. By offering insurance plans alongside treatment, WideCells Group is acting as a pioneer in stem cell healthcare services in a global scale.
Investments and future
Following the IPO, raising £2 million, £1.72 million net of costs, the company has raised gross proceeds of £648,696 by way of a private placing. WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The use of stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.